J&J’s consumer pharmaceuticals valued at $40bn ahead of IPO – Kommersant
Johnson & Johnson's (J&J) consumer medicines division, which is being spun off into a separate company, is valued at $40...
Johnson & Johnson's (J&J) consumer medicines division, which is being spun off into a separate company, is valued at $40...